1 min read
Add as a preferred source on GoogleStarling Oncology, Inc. Revenue Beats Estimates by $1.11 Million in Q3
The company posted a 14-cent GAAP loss per share and positive adjusted EBITDA of $3.4 million. Cash and cash equivalents totaled $36.9 million as of Sept. 30.
Starling Oncology, Inc. (STLN) posted third-quarter 2026 revenue of $169.8 million, beating estimates by $1.11 million. GAAP earnings per share was a 14-cent loss, missing estimates by 9 cents.
Adjusted EBITDA was positive $3.4 million, compared with a loss of $3.5 million. Cash and cash equivalents totaled $36.9 million as of Sept. 30, 2026.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.